A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
Joel Randolph Hecht, Madhavan V. Pillai, Russell Gollard et al. · Clinical Colorectal Cancer · 2010
Cited by 72 works. doi:10.3816/ccc.2010.n.013
Authors
- Joel Randolph Hecht
- Madhavan V. Pillai
- Russell Gollard
- William J. Heim
- Forrest Swan
- Ravi Patel
- Lyndah K. Dreiling
- May F. Mo
- Imtiaz A. Malik
References
- Cancer Statistics, 2007
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
- Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant Chemotherapy
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
- First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
- Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer
- Fixed-dose Pegfilgrastim is Safe and Allows Neutrophil Recovery in Patients with Non-Hodgkin's Lymphoma
- Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use